docwirenews.com
Ustekinumab Dose Intensification in Crohn's Disease - Docwire News
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction, which affects treatment burden and planning.
Adults with Crohn’s disease on ustekinumab, patients experiencing secondary loss of response, clinicians deciding on dose intensification or switching therapy, and IBD researchers.
What To Know
What to know This article reports results of a randomized, multicenter trial testing two ustekinumab dose-intensification strategies for adults with Crohn’s disease who had a secondary loss of response on maintenance ustekinumab.
All patients received a single intravenous reinduction (~6 mg/kg) and were then randomized to subcutaneous 90 mg every 4 weeks versus every 8 weeks through week 48.
The trial found no clear benefit to routine 4-weekly subcutaneous dosing after intravenous reinduction: steroid-free clinical remission at week 48 was similar between groups (about 15% vs 19%), and higher serum concentrations did not predict better clinical or endoscopic outcomes. Serious adverse event rates were similar.
What this means for treatment choices: if a single IV reinduction does not recapture response within ~24 weeks, the study suggests little reason to escalate to 4-weekly maintenance routinely; consider switching to an alternative advanced therapy rather than ongoing intensification beyond 6 months.
Practical takeaways: this is a prospective randomized trial across multiple centers, so the findings carry meaningful weight for decisions about ustekinumab intensification. Discuss options with your gastroenterology team, especially if you have not regained clear clinical response after an IV reinduction.
The study's primary endpoint was steroid-free clinical remission at week 48 and included fecal calprotectin as an objective marker. Clinical remission after IV reinduction was usually achieved within 24 weeks, with no added benefit beyond 6 months—so lack of response by that time favors switching therapies. As always, individual patient factors and clinician judgment matter.
